{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["3(6)"],"submitter":["Terzo E"],"funding":["n/a"],"pubmed_abstract":["Ribosomes in cancer cells accumulate numerous patient-specific structural and functional modifications that facilitate tumor progression by modifying protein translation. We have taken a unique synthetic chemistry approach to generate novel macrolides, Ribosome modulating agents (RMA), that are proposed to act distal to catalytic sites and exploit cancer ribosome heterogeneity. The RMA ZKN-157 shows two levels of selectivity: (i) selective translation inhibition of a subset of proteins enriched for components of the ribosome and protein translation machinery that are upregulated by MYC; and (ii) selective inhibition of proliferation of a subset of colorectal cancer cell lines. Mechanistically, the selective ribosome targeting in sensitive cells triggered cell-cycle arrest and apoptosis. Co"],"journal":["Cancer research communications"],"pagination":["969-979"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10241187"],"repository":["biostudies-literature"],"pubmed_title":["A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer."],"pmcid":["PMC10241187"],"pubmed_authors":["Padhye S","Shi S","Wang C","Austin W","Apte SA","Sidransky D","Reddy A","Clark RB","Caponegro M","Modur V","Rashed S","Badarinarayana V","Terzo E"],"additional_accession":[]},"is_claimable":false,"name":"A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer.","description":"Ribosomes in cancer cells accumulate numerous patient-specific structural and functional modifications that facilitate tumor progression by modifying protein translation. We have taken a unique synthetic chemistry approach to generate novel macrolides, Ribosome modulating agents (RMA), that are proposed to act distal to catalytic sites and exploit cancer ribosome heterogeneity. The RMA ZKN-157 shows two levels of selectivity: (i) selective translation inhibition of a subset of proteins enriched for components of the ribosome and protein translation machinery that are upregulated by MYC; and (ii) selective inhibition of proliferation of a subset of colorectal cancer cell lines. Mechanistically, the selective ribosome targeting in sensitive cells triggered cell-cycle arrest and apoptosis. Co","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2026-05-29T03:28:00.174Z","creation":"2024-12-04T08:15:08.048Z"},"accession":"S-EPMC10241187","cross_references":{"pubmed":["37377612"],"doi":["10.1158/2767-9764.CRC-22-0469"]}}